|
WO2021055809A1
|
|
Methods and probiotic compositions for the treatment of metabolic diseases and disorders
|
|
WO2021011456A1
|
|
Ehrlichia vaccines and immunogenic compositions
|
|
US2020187790A1
|
|
Multi-channel orthogonal convolutional neural networks
|
|
WO2020069282A1
|
|
Methods and probiotic compositions for the treatment of bone disorders
|
|
WO2020023950A1
|
|
Chimeric immunogenic polypeptides
|
|
AU2019267569A1
|
|
Immunoreactive polypeptides
|
|
US2019231805A1
|
|
Shp2 inhibitors and methods of use thereof
|
|
WO2019108777A1
|
|
Elimination of proliferating cells from stem cell-derived grafts
|
|
AU2018358144A1
|
|
Methods for predicting kinase inhibitor resistance
|
|
AU2018346252A1
|
|
Systems and methods for coronary occlusion treatment
|
|
CA3072099A1
|
|
Engineered antibody fc variants for enhanced serum half life
|
|
US2018348134A1
|
|
Apparatus and methods for endometrial tissue identification
|
|
US2019352646A1
|
|
Steap2 inhibitors for the treatment of liver cancers
|
|
EP3478325A1
|
|
Elimination of proliferating cells from stem cell-derived grafts
|
|
AU2017277784A1
|
|
Systems and methods for automated coronary plaque characterization and risk assessment using intravascular optical coherence tomography
|
|
EP3417058A1
|
|
Sortase-modified molecules and uses thereof
|
|
AU2016219511A1
|
|
Engineered immunoglobulin Fc polypeptides displaying improved complement activation
|
|
AU2014331923A1
|
|
Monoclonal Olfml-3 antibodies and uses thereof
|
|
EP3041831A1
|
|
Alpha-tea salt forms: compositions and uses for treating disease
|
|
AU2014203006A1
|
|
Recombinant filaggrin polypeptides for cell importation
|
